Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +52.39%
#2 Pons Pons +47.46%
#3 TENDIES TENDIES +46.80%
#4 PondCoin PondCoin +43.65%
#5 Magma Finance Magma Finance +34.04%
#6 StonkBroker StonkBroker +31.98%
#7 Purr Purr +30.11%
#8 Starpower Starpower +29.64%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 SkyAI SkyAI +26.28%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Classifica tra le azioni #28895
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Prezzo delle azioni
$0.0573
Capitalizzazione di mercato
$24.08M
Variazione (1 giorno)
0.53%
Variazione (1 anno)
-28.55%
Paese
US
Scambia Provectus Biopharmaceuticals, Inc. (PVCT)

Categoria

Healthcare
Numero di azioni in circolazione per Provectus Biopharmaceuticals, Inc. (PVCT)
Numero di azioni in circolazione al August 2026: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Provectus Biopharmaceuticals, Inc., il numero attuale di azioni in circolazione è 0. Alla fine del August 2026, la società aveva 0 azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Provectus Biopharmaceuticals, Inc. (PVCT) dal 2026 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
Non abbastanza dati per le date fornite.
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH